Thank you very much for that.
Dr. Lee, on March 5 of this year, Dr. Edwards of the Structural Genomics Consortium was before this committee, and he noted that the vast majority of biomedical research focuses on a very small number of well-understood proteins, often ones where there are tools readily available for their study.
He suggested that researchers and funding agencies should be less risk averse. In your view, is risk aversion, in the sense of uncertainty of financial benefits, a factor in the challenge to encourage research in the area of rare diseases, and is Health Canada able to help offset risk aversion by supporting research on rare diseases? Could you share some of the initiatives that might be of assistance to that end?